Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure

BMJ Case Rep. 2019 Feb 21;12(2):e227676. doi: 10.1136/bcr-2018-227676.

Abstract

We present a novel treatment protocol that was successful in the management of Hodgkin's-associated vanishing bile duct syndrome, a rare but serious complication of Hodgkin's lymphoma. We believe that publication of this treatment protocol and the rationale for its development will be of interest to anyone faced with treating this challenging condition.

Keywords: haematology (drugs and medicines); liver disease; malignant and benign haematology.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Bile Duct Diseases / drug therapy*
  • Bile Duct Diseases / etiology
  • Bile Duct Diseases / pathology
  • Brentuximab Vedotin
  • Cyclophosphamide
  • Disease Progression
  • Female
  • Hodgkin Disease / complications
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / pathology
  • Humans
  • Immunoconjugates / administration & dosage
  • Jaundice, Obstructive / drug therapy*
  • Jaundice, Obstructive / pathology
  • Liver Failure / drug therapy
  • Liver Failure / etiology
  • Liver Failure / pathology*
  • Liver Function Tests
  • Prednisolone / administration & dosage
  • Procarbazine / administration & dosage
  • Remission Induction
  • Treatment Outcome

Substances

  • Immunoconjugates
  • Procarbazine
  • Brentuximab Vedotin
  • Cyclophosphamide
  • Prednisolone